Mimedx (MDXG) Non Operating Income (2023 - 2026)
Mimedx (MDXG) posted Non Operating Income of $788000.0 for Q2 2026, down 11.06% sequentially from $886000.0 in Q1 2026, and up 6.78% YoY from $738000.0 in Q2 2025.
Mimedx (MDXG) Non Operating Income (2023 - 2026) Analysis & Trends
Mimedx has reported Non Operating Income for 4 years, with the latest figure at $788000.0 in Q2 2026.
- Quarterly Non Operating Income rose 6.78% year-over-year to $788000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $3.4 million (up 74.7% YoY) and the FY2025 annual result came in at $2.9 million, up 391.55% from the prior year.
- Non Operating Income fell to $788000.0 in Q2 2026 per MDXG's latest filing, from $886000.0 in the prior quarter.
- Over five years, Non Operating Income peaked at $904000.0 in Q4 2025 and troughed at -$1.7 million in Q1 2024.
- A 4-year average of -$100153.8 and a median of $403000.0 in 2024 frame the typical range for Non Operating Income.
- The sharpest annual moves came in 2025 and 2026: Non Operating Income jumped 24500.0% in 2025, then increased 6.78% in 2026.
- Over 4 years, Non Operating Income stood at -$1.6 million in 2023, then soared by 125.3% to $403000.0 in 2024, then jumped by 124.32% to $904000.0 in 2025, then fell by 12.83% to $788000.0 in 2026.
- According to Business Quant data, Non Operating Income over the past three periods registered $788000.0, $886000.0, and $904000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -139.24 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 12.40 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -51.63 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -53.64 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Mimedx | 622.24 Mn | 486.40 Mn | 44.38 Mn | 788,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 788,000.00 |
| Mar 31, 2026 | 886,000.00 |
| Dec 31, 2025 | 904,000.00 |
| Sep 30, 2025 | 785,000.00 |
| Jun 30, 2025 | 738,000.00 |
| Mar 31, 2025 | 506,000.00 |
| Dec 31, 2024 | 403,000.00 |
| Sep 30, 2024 | 278,000.00 |
| Jun 30, 2024 | 3,000.00 |
| Mar 31, 2024 | -1.69 Mn |
| Dec 31, 2023 | -1.59 Mn |
| Sep 30, 2023 | -1.68 Mn |
| Jun 30, 2023 | -1.63 Mn |